Stephen Russell, president and CEO of Vyriad (Vyriad)
Regeneron-backed oncolytic virus startup scores modest Series B extension
Three years ago, Regeneron collaborated with tiny, Rochester, MN biotech Vyriad to kickstart a Phase II trial. That collaboration deal would combine Regeneron’s PD-1 drug Libtayo with the biotech’s Voyager-V1 program, an oncolytic virus derived from the Vesicular stomatitis virus.
The trial was looking at multiple types of cancer such as melanoma, lung, liver and endometrial cancers. And while the deal with Regeneron is ongoing, it looks like other backers — even from outside the pharmaceutical and biotech industries — now want in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
